You are about to leave a GSK website
You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content.
Data from a retrospective cohort study assessing the clinical presentation of HZO. A total of 869 patients with acute HZO seen at a single center from 2006 to 2016 were included in the analysis (age range from 1.3 to 100.2 years; median age at presentation 65.5 years). Among patients in this study, ~10% were immunocompromised. All outcomes were determined by direct chart review. Moderate vision loss was defined as best-corrected visual acuity of ≤20/50 and severe vision loss was vision ≤20/200.5
Data from a US retrospective cohort study assessing commercial health insurance claims in immunocompetent adults ≥50 years with a diagnosis of shingles (N=236,180) from 2008 to 2013.2
Cutaneous complications included cellulitis and zoster gangrenosum.2
Data from a US retrospective cohort study assessing commercial health insurance claims in immunocompetent adults ≥50 years with a diagnosis of shingles (N=236,180) from 2008-2013.2
Neurologic complications included aseptic meningitis, cranial nerve palsies, deafness, diaphragmatic paralysis, encephalitis, motor neuropathy, sensory loss, transverse myelitis, Guillain-Barré syndrome, hemiparesis, Bell’s palsy.2
Data from a population-based community cohort study (January 1986 to October 2011) in adult residents of Olmsted County, Minnesota, 50 years and older; this retrospective study compared rates of post-HZ stroke with a cohort of age and sex-matched individuals. Risk was adjusted for several known risk factors and confounding factors for stroke. Among the patients with HZ (n=4478), 0.7% had a stroke within 3 months post-HZ compared to 0.4% in the non-HZ cohort (n=16,800).3
Other people's experiences may be different.